{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:52:30Z","timestamp":1793242350950,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"am","delay-in-days":154,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32 DA007294"],"award-info":[{"award-number":["T32 DA007294"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG1 DA013035"],"award-info":[{"award-number":["UG1 DA013035"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jsat.2021.108447","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T12:04:05Z","timestamp":1619784245000},"page":"108447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse"],"prefix":"10.1016","volume":"131","author":[{"given":"Miranda G.","family":"Greiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matisyahu","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tse-Hwei","family":"Choo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Scodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Pavlicova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee N.C.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Fishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rotrosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward V.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2021.108447_bb0005","series-title":"Provisional drug overdose death counts","author":"Ahmad","year":"2020"},{"key":"10.1016\/j.jsat.2021.108447_bb0010","series-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013"},{"issue":"1","key":"10.1016\/j.jsat.2021.108447_bb0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11420-018-9643-3","article-title":"Improvement in residents\u2019 attitudes toward individuals with substance use disorders following an online training module on stigma","volume":"15","author":"Avery","year":"2019","journal-title":"HSS Journal\u00ae"},{"issue":"3","key":"10.1016\/j.jsat.2021.108447_bb0020","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jsat.2013.04.002","article-title":"Perceived relapse risk and desire for medication assisted treatment among persons seeking inpatient opiate detoxification","volume":"45","author":"Bailey","year":"2013","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"10","key":"10.1016\/j.jsat.2021.108447_bb0025","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1176\/appi.ps.201400140","article-title":"Stigma, discrimination, treatment effectiveness, and policy: Public views about drug addiction and mental illness","volume":"65","author":"Barry","year":"2014","journal-title":"Psychiatric Services (Washington, D.C.)"},{"key":"10.1016\/j.jsat.2021.108447_bb0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jsat.2014.12.011","article-title":"Discontinuation of buprenorphine maintenance therapy: Perspectives and outcomes","volume":"52","author":"Bentzley","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"9","key":"10.1016\/j.jsat.2021.108447_bb0035","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-159-9-201311050-00005","article-title":"Mortality after prison release: Opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009","volume":"159","author":"Binswanger","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"10.1016\/j.jsat.2021.108447_bb0040","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/BF02287318","article-title":"The long-term outcomes of drug use by methadone maintenance patients","volume":"30","author":"Bovasso","year":"2003","journal-title":"The Journal of Behavioral Health Services & Research"},{"issue":"1\u20132","key":"10.1016\/j.jsat.2021.108447_bb0045","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0376-8716(99)00063-0","article-title":"Inpatient opiate detoxification in Geneva: Follow-up at 1 and 6\u00a0months","volume":"58","author":"Broers","year":"2000","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.jsat.2021.108447_bb0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1081\/ADA-100103117","article-title":"One-, three-, and six-month outcomes after brief inpatient opioid detoxification","volume":"27","author":"Chutuape","year":"2001","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"issue":"8","key":"10.1016\/j.jsat.2021.108447_bb0055","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1377\/hlthaff.2010.0532","article-title":"The evidence doesn\u2019t justify steps by state medicaid programs to restrict opioid addiction treatment with buprenorphine","volume":"30","author":"Clark","year":"2011","journal-title":"Health Affairs"},{"issue":"2","key":"10.1016\/j.jsat.2021.108447_bb0060","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","article-title":"Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial","volume":"63","author":"Comer","year":"2006","journal-title":"Archives of General Psychiatry"},{"issue":"8","key":"10.1016\/j.jsat.2021.108447_bb0065","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/add.12551","article-title":"The global epidemiology and burden of opioid dependence: Results from the global burden of disease 2010 study","volume":"109","author":"Degenhardt","year":"2014","journal-title":"Addiction (Abingdon, England)"},{"issue":"3","key":"10.1016\/j.jsat.2021.108447_bb0070","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/ADM.0000000000000302","article-title":"Open-label study of injectable extended-release naltrexone (XR-NTX) in healthcare professionals with opioid dependence","volume":"11","author":"Earley","year":"2017","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2021.108447_bb0075","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.drugalcdep.2017.03.013","article-title":"Effectiveness of treatment for opioid use disorder: A national, five-year, prospective, observational study in England","volume":"176","author":"Eastwood","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108447_bb0080","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000000592","article-title":"Treatment trajectories during and after a medication trial for opioid use disorder: Moving from research as usual to treatment as usual","author":"Fishman","year":"2020","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2021.108447_bb0085","doi-asserted-by":"crossref","first-page":"107527","DOI":"10.1016\/j.drugalcdep.2019.06.029","article-title":"U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018","volume":"204","author":"Ghertner","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108447_bb0090","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1192\/bjp.154.3.348","article-title":"Lapse, relapse and survival among opiate addicts after treatment. A prospective follow-up study","volume":"154","author":"Gossop","year":"1989","journal-title":"The British Journal of Psychiatry: The Journal of Mental Science"},{"issue":"2","key":"10.1016\/j.jsat.2021.108447_bb0095","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/HRP.0000000000000052","article-title":"Long-term course of opioid addiction","volume":"23","author":"Hser","year":"2015","journal-title":"Harvard Review of Psychiatry"},{"issue":"4","key":"10.1016\/j.jsat.2021.108447_bb0100","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/add.13238","article-title":"Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial","volume":"111","author":"Hser","year":"2016","journal-title":"Addiction (Abingdon, England)"},{"issue":"5","key":"10.1016\/j.jsat.2021.108447_bb0105","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1001\/archpsyc.58.5.503","article-title":"A 33-year follow-up of narcotics addicts","volume":"58","author":"Hser","year":"2001","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1016\/j.jsat.2021.108447_bb0110","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/ADM.0000000000000274","article-title":"Distinctive trajectories of opioid use over an extended follow-up of patients in a multisite trial on buprenorphine\u00a0+\u00a0naloxone and methadone","volume":"11","author":"Hser","year":"2017","journal-title":"Journal of Addiction Medicine"},{"issue":"1","key":"10.1016\/j.jsat.2021.108447_bb0115","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/j.jsat.2021.108447_bb0120","series-title":"Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]","article-title":"Efficacy of maintenance treatment with naltrexone for opioid dependence: A meta-analytical review","author":"Johansson","year":"2006"},{"issue":"2","key":"10.1016\/j.jsat.2021.108447_bb0125","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0376-8716(01)00120-X","article-title":"Differences among out-of-treatment drug injectors who use stimulants only, opiates only or both: Implications for treatment entry","volume":"64","author":"John","year":"2001","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108447_bb0130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jsat.2018.07.008","article-title":"Comparison between buprenorphine provider availability and opioid deaths among US counties","volume":"93","author":"Jones","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108447_bb0135","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1046\/j.1360-0443.2002.00217.x","article-title":"A systematic review on the efficacy of naltrexone treatment in opioid dependence","volume":"97","author":"Kirchmayer","year":"2002","journal-title":"Addiction (Abingdon, England)"},{"issue":"2","key":"10.1016\/j.jsat.2021.108447_bb0140","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/10550881003684798","article-title":"Pharmacotherapy in the treatment of addiction: Methadone","volume":"29","author":"Kreek","year":"2010","journal-title":"Journal of Addictive Diseases"},{"issue":"9","key":"10.1016\/j.jsat.2021.108447_bb0145","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/add.12208","article-title":"Injectable extended-release naltrexone (XR-NTX) for opioid dependence: Long-term safety and effectiveness","volume":"108","author":"Krupitsky","year":"2013","journal-title":"Addiction (Abingdon, England)"},{"issue":"9776","key":"10.1016\/j.jsat.2021.108447_bb0150","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet (London, England)"},{"issue":"9","key":"10.1016\/j.jsat.2021.108447_bb0155","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1001\/archgenpsychiatry.2012.1a","article-title":"Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence","volume":"69","author":"Krupitsky","year":"2012","journal-title":"Archives of General Psychiatry"},{"issue":"13","key":"10.1016\/j.jsat.2021.108447_bb0160","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders","volume":"374","author":"Lee","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.jsat.2021.108447_bb0165","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s11606-008-0866-8","article-title":"Home buprenorphine\/naloxone induction in primary care","volume":"24","author":"Lee","year":"2009","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.jsat.2021.108447_bb0170","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cct.2016.08.004","article-title":"NIDA clinical trials network CTN-0051, extended-release naltrexone vs. buprenorphine for opioid treatment (X:BOT): Study design and rationale","volume":"50","author":"Lee","year":"2016","journal-title":"Contemporary Clinical Trials"},{"issue":"10118","key":"10.1016\/j.jsat.2021.108447_bb0175","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"8","key":"10.1016\/j.jsat.2021.108447_bb0180","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jamainternmed.2014.2556","article-title":"Buprenorphine treatment for hospitalized, opioid-dependent patients: A randomized clinical trial","volume":"174","author":"Liebschutz","year":"2014","journal-title":"JAMA Internal Medicine"},{"key":"10.1016\/j.jsat.2021.108447_bb0185","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"2","author":"Mattick","year":"2003","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2021.108447_bb0190","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"3","author":"Mattick","year":"2004","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2021.108447_bb0195","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.drugalcdep.2017.06.028","article-title":"Treatment use, sources of payment, and financial barriers to treatment among individuals with opioid use disorder following the national implementation of the ACA","volume":"179","author":"McKenna","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"13","key":"10.1016\/j.jsat.2021.108447_bb0200","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","article-title":"Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation","volume":"284","author":"McLellan","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jsat.2021.108447_bb0205","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jsat.2017.04.016","article-title":"Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone","volume":"85","author":"Nunes","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108447_bb0210","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cct.2016.09.006","article-title":"Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence","volume":"51","author":"Nunes","year":"2016","journal-title":"Contemporary Clinical Trials"},{"issue":"5","key":"10.1016\/j.jsat.2021.108447_bb0215","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.euroneuro.2005.11.001","article-title":"A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence","volume":"16","author":"Roozen","year":"2006","journal-title":"European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.jsat.2021.108447_bb0220","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1370\/afm.1735","article-title":"Geographic and specialty distribution of US physicians trained to treat opioid use disorder","volume":"13","author":"Rosenblatt","year":"2015","journal-title":"Annals of Family Medicine"},{"key":"10.1016\/j.jsat.2021.108447_bb0225","series-title":"Handbook of psychiatric measures","first-page":"477","article-title":"Alcohol timeline followback (TLFB)","author":"Sobell","year":"2000"},{"issue":"10","key":"10.1016\/j.jsat.2021.108447_bb0230","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1111\/add.14278","article-title":"Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: A 9-month follow-up to a 3-month randomized trial","volume":"113","author":"Solli","year":"2018","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/j.jsat.2021.108447_bb0235","series-title":"Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001; NSDUH Series H-55, p. 114)","author":"Substance Abuse and Mental Health Services Administration","year":"2019"},{"issue":"5","key":"10.1016\/j.jsat.2021.108447_bb0240","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1176\/appi.ajp.2011.11071121","article-title":"Naltrexone implant for the treatment of polydrug dependence: A randomized controlled trial","volume":"169","author":"Tiihonen","year":"2012","journal-title":"The American Journal of Psychiatry"},{"issue":"1","key":"10.1016\/j.jsat.2021.108447_bb0245","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: A systematic review","volume":"35","author":"Timko","year":"2016","journal-title":"Journal of Addictive Diseases"},{"issue":"12","key":"10.1016\/j.jsat.2021.108447_bb0250","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial","volume":"68","author":"Weiss","year":"2011","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.jsat.2021.108447_bb0255","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.02.030","article-title":"Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study","volume":"150","author":"Weiss","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.jsat.2021.108447_bb0260","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/ajad.12527","article-title":"Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders","volume":"26","author":"Williams","year":"2017","journal-title":"The American Journal on Addictions"},{"issue":"1","key":"10.1016\/j.jsat.2021.108447_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00952990.2018.1546862","article-title":"Development of a cascade of care for responding to the opioid epidemic","volume":"45","author":"Williams","year":"2019","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"issue":"3","key":"10.1016\/j.jsat.2021.108447_bb0270","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.drugalcdep.2005.08.010","article-title":"The effect of persistence of cocaine use on 12-month outcomes for the treatment of heroin dependence","volume":"81","author":"Williamson","year":"2006","journal-title":"Drug and Alcohol Dependence"}],"updated-by":[{"DOI":"10.1016\/j.jsat.2021.108566","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000}}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221001732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221001732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T16:06:04Z","timestamp":1677945964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547221001732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":54,"alternative-id":["S0740547221001732"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108447","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108447","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108447"}}